Welcome to our dedicated page for CSL SP/ADR news (Ticker: CSLLY), a resource for investors and traders seeking the latest updates and insights on CSL SP/ADR stock.
CSL LTD SP/ADR (CSL) is a global biotechnology company known for its innovative therapies in iron deficiency and nephrology. Headquartered in St. Gallen, Switzerland, CSL Vifor, a division of CSL, focuses on strategic global partnerships, innovative pharmaceuticals, and precision healthcare solutions. Their portfolio includes Ferinject, an IV iron therapy with marketing authorization in 87 countries as of 2024, addressing iron deficiency anemia and heart failure in adults and pediatric patients. With a workforce of 32,000, CSL delivers life-saving products worldwide, striving to improve patients' quality of life.
Rhea-AI Summary
CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics receive historic approval for ARCT-154, the world's first Self-Amplifying messenger RNA (sa-mRNA) COVID-19 Vaccine in Japan. This marks a significant milestone in CSL's promise to develop and deliver innovative vaccines to combat respiratory viral diseases, expanding their comprehensive portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
Rhea-AI Summary
CSL (CSL; CSLLY) and Arcturus Therapeutics announced that Japan's Ministry of Health, Labor and Welfare granted approval for ARCT-154, a self-amplifying mRNA COVID-19 vaccine. This marks the first sa-mRNA vaccine in the world to be registered, highlighting CSL's commitment to global public health. The vaccine is approved for initial vaccination and booster for adults 18 years and older, based on positive clinical data from several studies. CSL Seqirus, in partnership with Meiji Seika Pharma, will distribute the vaccine in Japan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.8%
Tags
-
News
Rhea-AI Summary
On November 24, 2023, the global coalition for Iron Deficiency Day is focusing on the importance of early diagnosis and treatment of iron deficiency and anemia. This initiative aims to raise awareness about the serious health impact of these conditions and their effect on quality of life. The company involved in this initiative is not specified in the press release.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
Rhea-AI Summary
Global biotechnology leader CSL and uniQure N.V. have won the 2023 Prix Galien USA Award for Best Product for Rare/Orphan Diseases for their gene therapy HEMGENIX®. HEMGENIX is the first and only FDA-approved gene therapy for adults with hemophilia B. It has also received conditional marketing authorization in the European Union and Canada.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.54%
Tags
-
Rhea-AI Summary
CSL Seqirus announces new data supporting the effectiveness and value of cell-based and adjuvanted seasonal influenza vaccines
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
-
Rhea-AI Summary
CSL Seqirus presents new real-world evidence studies on influenza vaccination at ESWI Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
News
Rhea-AI Summary
CSL Seqirus selected by BARDA to deliver H5N8 A/Astrakhan antigen to the U.S. government for pandemic response readiness
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
-
Rhea-AI Summary
ESC guidelines upgrade recommendations for IV iron supplementation in the treatment of iron deficiency in HF patients, positively impacting CSL Vifor's Ferinject®. IV iron supplementation is recommended to alleviate HF symptoms and improve quality of life. Additionally, results from the HEART-FID trial show a modest benefit in HF outcomes with ferric carboxymaltose. Pooled analysis of long-term trials also demonstrates reduced risks of hospitalization due to HF or cardiovascular causes with ferric carboxymaltose.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
-
Rhea-AI Summary
CSL, a global biotechnology leader, has appointed Jeffrey Ball as its Chief Sustainability Officer. Ball has been with CSL since 2019 and has played a vital role in the evolution of the company's Sustainability Strategy. As Chief Sustainability Officer, Ball will oversee the expansion and operationalization of key sustainability targets and initiatives. CSL's Sustainability Strategy focuses on Environment, Social and Sustainable Workforce, with strong Governance underpinning all pillars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
News
Rhea-AI Summary
CSL Seqirus has begun shipping its portfolio of innovative influenza vaccines across the U.S. for the 2023/24 influenza season. The company aims to supply over 55 million doses to healthcare providers. CSL Seqirus offers differentiated vaccine options approved for individuals aged six months and older. The portfolio includes FLUCELVAX QUADRIVALENT, the first and only cell-based quadrivalent influenza vaccine; FLUAD QUADRIVALENT, the first and only adjuvanted quadrivalent seasonal influenza vaccine for adults 65 years and older; and AFLURIA QUADRIVALENT, an egg-based quadrivalent influenza vaccine. Vaccination rates were low during the previous year, despite a significant increase in influenza cases, especially in children.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
FAQ
What is the current stock price of CSL SP/ADR (CSLLY)?
The current stock price of CSL SP/ADR (CSLLY) is $86.54 as of December 20, 2024.
What is the market cap of CSL SP/ADR (CSLLY)?
The market cap of CSL SP/ADR (CSLLY) is approximately 87.7B.
What is CSL LTD SP/ADR known for?
CSL is known for its innovative therapies in iron deficiency and nephrology, focusing on precision healthcare solutions.
Where is CSL LTD SP/ADR headquartered?
CSL LTD SP/ADR is headquartered in St. Gallen, Switzerland.
What is CSL Vifor's specialization?
CSL Vifor focuses on strategic global partnerships, innovative pharmaceuticals, and precision healthcare solutions.
What is Ferinject?
Ferinject is an IV iron therapy marketed in 87 countries, addressing iron deficiency anemia and heart failure in adults and pediatric patients.
How many countries does CSL deliver its products to?
CSL delivers life-saving therapies to people in more than 100 countries worldwide.
CSL LTD SP/ADR